Marrying Activase with Gleevec

Research by a team of Swedish and American scientists suggests that combining a tissue plasminogen activator with a platelet derived growth factor receptor inhibitor may result in improved outcomes for stroke therapy. This may help widen the therapeutic window for Genentech Inc.'s

Activase alteplase, the only recombinant tissue plasminogen activator approved to treat acute ischemic stroke, by combining it with Novartis AG's Gleevec imatinib, a platelet derived growth factor receptor A inhibitor...